Tag: Natera
Natera announces enrolment completion for RenaCARE study
Natera has announced full enrolment for the RenaCARE (Renasight Clinical Application, Review and Evaluation) study—a real-world, prospective, multicentre trial to assess the clinical utility...
Natera showcases new data on Prospera and Renasight tests at American...
Natera today announced the presentation of data on the clinical utility of its Prospera and Renasight tests across a total of 14 sessions at...
Natera announces study results showing “excellent” positive predictive value of Prospera...
Natera has announced the results of a large clinical experience study confirming the "strong performance" of its Prospera donor-derived cell-free DNA (dd-cfDNA) test in...
Natera validates kidney transplant rejection test in multicentre, prospective Trifecta study
Natera has announced initial results from the global, multicentre, prospective Trifecta study, which assessed its Prospera with quantification test for kidney transplant rejection and was led by Phil...
Natera launches Prospera with quantification to improve kidney graft rejection testing
Natera has announced the launch of Prospera with quantification, the only cell-free DNA (cfDNA) test for kidney rejection that provides three values—the quantity of...